BioLife Solutions (BLFS)
(Delayed Data from NSDQ)
$23.44 USD
+0.84 (3.72%)
Updated Oct 14, 2024 03:59 PM ET
After-Market: $23.42 -0.02 (-0.09%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$23.44 USD
+0.84 (3.72%)
Updated Oct 14, 2024 03:59 PM ET
After-Market: $23.42 -0.02 (-0.09%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth B Momentum B VGM
Zacks News
Community Health (CYH) to Divest Two NC Hospitals for $320M
by Zacks Equity Research
Community Health (CYH) expects the North Carolina hospitals' divestment to close at a later part of this year.
Humana (HUM), CD&R Backed Gentiva to Buy Assets From ProMedica
by Zacks Equity Research
The acquisition is expected to boost Humana (HUM) and CD&R backed Gentiva's reach to over 500 locations.
Acadia Healthcare (ACHC) Q4 Earnings Miss on Rising Costs
by Zacks Equity Research
Acadia Healthcare's (ACHC) 2023 capital expenditure for expansion initiatives is predicted to stay between $350 million and $400 million.
Is Annovis Bio (ANVS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Annovis Bio, Inc. (ANVS) and BioLife Solutions, Inc. (BLFS) have performed compared to their sector so far this year.
BioLife Solutions, Inc. (BLFS) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -27.78% and 2.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
BioLife Solutions, Inc. (BLFS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -755% and 3.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
SurModics (SRDX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of 12.82% and 2.46%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
BioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of 29.17% and 4.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Cerus (CERS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cerus (CERS) delivered earnings and revenue surprises of 30% and 2.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
NuVasive (NUVA) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
NuVasive (NUVA) delivered earnings and revenue surprises of 42.11% and 4.84%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for May 2nd
by Zacks Equity Research
ALEC, AMRS, and BLFS have been added to the Zacks Rank #5 (Strong Sell) List on May 2, 2022
New Strong Sell Stocks for March 31st
by Zacks Equity Research
BLFS, CRNT, and AMBA have been added to the Zacks Rank #5 (Strong Sell) List on March 31, 2022.
BioLife Solutions, Inc. (BLFS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -131.25% and 0.06%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
PETQ or BLFS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PETQ vs. BLFS: Which Stock Is the Better Value Option?
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Analysts Estimate BioLife Solutions, Inc. (BLFS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
BioLife Solutions, Inc. (BLFS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
BioLife Solutions, Inc. (BLFS) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of 480.00% and 10.19%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
BioLife Solutions, Inc. (BLFS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
BioLife Solutions, Inc. (BLFS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Medtronic (MDT) Reports Economic Findings on PRODIGY Data
by Zacks Equity Research
Medtronic (MDT)-sponsored PRODIGY Trial data was used to analyze cost benefits and outcomes from continuous pulse oximetry and capnography monitoring in high-risk patients.
Company News for May 17, 2021
by Zacks Equity Research
Companies In The News Are: ACB, NEWR, BLFS, GLOB
BioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of 40.00% and 8.01%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: BioLife Solutions, Inc. (BLFS) Q1 Earnings Expected to Decline
by Zacks Equity Research
BioLife Solutions, Inc. (BLFS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.